Project ECHO: Type 1 Diabetes Care and Management

Each ECHO will have a live, interactive seminar and on-demand component; please note that participation in the live event is limited to 25 persons per event and that those who participate in the live ECHO may receive credit from the live event but are not eligible to receive credit for the on-demand webinar. 

We are pleased to participate in Project ECHO: Type 1 Diabetes Care and Management.

Open to all clinicians, this program seeks to educate primary care providers, care teams, and non-diabetes specialists in best practices for type 1 diabetes care and management. With many therapeutic and pharmacological options available, clinicians need additional resources to stay up-to-date. This program, featuring live, interactive seminars and on-demand webinars, will focus on evidence-based methods for addressing type 1 diabetes with a goal of improving health-related quality-of-life for patients and empowering clinicians to provide the best possible care. The aim is to address type 1 diabetes by educating clinicians around the world in best-practices and research directly from diabetes-management specialists. There will be a total of 7 ECHOs, each focusing on a different approach to managing type 1 diabetes. 

Project ECHO started at the University of New Mexico in 2003. ECHO stands for Extension of Community Healthcare Outcomes, and it is built on the idea that while not everyone can be a specialist, all patients deserve access to specialty care. Using a hub and spoke model, and virtual platforms like Zoom, specialists are able to connect with non-specialist providers in real time to provide education and feedback on cases. Our ECHOs, which will focus on the management of type 1 diabetes, will be held on a monthly basis as live and on-demand webinars. This educational activity is supported by independent medical educational grants from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, Novo Nordisk Inc., and Tandem Diabetes Care. 

As registration opens for each individual ECHO, you can click each hyperlink below to learn more about the upcoming ECHO. You can review speakers and topics in the program tab. Once registered for the ECHO, you will be able to submit a case or question on that topic. 

ECHO 1: Engaging With People with Type 1 Diabetes

ECHO 2 Topic: Using Insulin in Type 1 Diabetes

ECHO 3 Topic: Insulin Pumps in Type 1 Diabetes

ECHO 4 Topic: Telehealth and Type 1 Diabetes

ECHO 5 Topic: Type 1 Diabetes and Neuropathy

ECHO 6 Topic: Professional and Personal Use of CGM in Clinical Practice

ECHO 7 Topic: Exercise Management and Type 1 Diabetes

Target Audience

This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, type 1 diabetes and associated diseases. Additionally, this program may be of interest to primary care professionals, care teams, and advance practice professionals who treat patients with type 1 diabetes.

Learning Objectives

Upon completing this series, learners will be able to:

  • Identify new and emerging trends in type 1 diabetes management, including emerging therapeutic options;
  • Develop individualized treatment strategies, that include a variety of approaches, to manage individuals with T1D and associated comorbidities; 
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with T1D.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Activity summary
Course opens: 
Course expires: 

Each ECHO will have a live and on-demand component; please note that participation in the live event is limited to 25 persons per event and that those who participate in the live ECHO may receive credit from the live event but are not eligible to receive credit for the on-demand webinar. 



Planned Date of ECHO
1. Engaging With People with Type 1 Diabetes

Korey Hood, PhD
(Stanford University)

Thursday, September 17, 2020
4pm PT, 5pm MT, 6pm CT, 7pm ET                                                     
2. Using Insulin in Type 1 Diabetes

Diana Isaacs, PharmD, BC-ADM, BCPS, CDCES
(Cleveland Clinic)

Thursday, October 15, 2020
4pm PT, 5pm MT, 6pm CT, 7pm ET
3. Insulin Pumps in Type 1 Diabetes

Daniel Katselnik, MD
(Diabetes and Metabolism Specialists)

Thursday, November 19, 2020
4pm PT, 5pm MT, 6pm CT, 7pm ET
4. Telehealth in Type 1 Diabetes

Ruth Weinstock, MD, PhD
(SUNY Upstate Medical University)

Thursday, December 17, 2020
4pm PT, 5pm MT, 6pm CT, 7pm ET
5. Type 1 Diabetes and Neuropathy

Lucia Novak, MSN, NP
(Capital Diabetes & Endocrine Associates)

Thursday, January 28, 2021
4pm PT, 5pm MT, 6pm CT, 7pm ET
6. Professional and Personal Use of CGM in Clinical Practice

Davida Kruger, MSN, APN-BC, BC-ADM 
(Henry Ford Health System)

Thursday, February 25, 2021
4pm PT, 5pm MT, 6pm CT, 7pm ET
7. Exercise Management in Type 1 Diabetes

Michael Riddell, PhD
(York University) 

Thursday, March 25, 2021
4pm PT, 5pm MT, 6pm CT, 7pm ET


Davida Kruger, MSN, APN-BC, BC-ADM (program chair)
Henry Ford Health System

Michael Riddell, PhD
York University

Diana Isaacs, PharmD, BC-ADM, BCPS, CDCES
Cleveland Clinic

Daniel Katselnik, MD
Diabetes and Metabolism Specialists

Ruth Weinstock, MD, PhD
SUNY Upstate Medical University

Lucia Novak, MSN, ANP-BC, BC-ADM
Capital Diabetes & Endocrine Associates

Korey Hood, PhD
Stanford University


Lorena Alarcon-Casas Wright, MD, FACE
Univeristy of Washington School of Medicine


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: 
Davida Kruger, MSN, APN-BC, BC-ADM: 
National Institutes of Health (NIH) - Partial Salary and Benefits; Abbott, Dexcom, Eli Lilly and Company, Pendulum, Janssen, Novo Nordisk, Sanofi Aventis, Xeris - Advisory Board; Abbott, AstraZeneca, BI/Lilly, Dexcom, Xeris, Janssen, Novo Nordisk, Lilly, Valeritas - Speakers Bureau; Abbott, Novo Nordisk, Helmsley Foundation, Dexcom - Grants/Research Support to Primary Employer.
Michael Riddell, PhD: Eli Lilly, Insulet, Medtronic, Novo Nordisk - Advisory Board, Speakers Bureau; Insulet - Grant Recipient; Novo Nordisk - Clinical Trials.
Korey Hood, PhD: Dexcom, Inc - Research Support for an Investigator-Initiated Project. Lifescan Diabetes Institute, Cecelia Health, Ceracor, MedIW - Consultant Fees for Educational Content.
Diana Isaacs, PharmD, BC-ADM, BCPS, CDCES: Abbott, Dexcom, Novo Nordisck, Xeris Pharmaceuticals - Speaker; Lifescan, Companion Medical - Consultant; American Diabetes Association - Professional Practice Committee.
Daniel Katselnik, MD:  Dexcom, Novo Nordisk, AstraZeneca - Speaker; JDRF - Chapter Board Member.
Lucia Novak, MSN, ANP-BC, BC-ADM:  Abbott Diabetes Care, AstraZeneca, Janssen, Novo Nordisk, Xeris - Speaker; Abbott Diabetes Care, Novo Nordisk, Xeris, Sanofi - Consultant; Abbott Diabetes Care, Janssen, Novo Nordisk, Xeris, Sanofi - Advisor.
Ruth Weinstock, MD, PhD: NIH, JDRF, Jaeb Center for Health Research, Unitio, Helmsley Charitable Trust - Grantee; NIH - Grant Reviewer; ADA, Wolters Kluwer - Author; ADA - Speaker; Jaeb Center for Health Research - Advisory Committee; Insulet Corp, Tolerion Inc, Eli Lilly and Co, Medtronic, Diasome Pharmaceuticals, Boehringer Ingelheim, Kowa Research Institute - Participation in Multicenter Clinical Trials - all grants awarded to institution. 

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewer reported no relevant financial relationships: 
Lorena Alarcon-Casas Wright, MD, FACE

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by independent medical educational grants from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, and Novo Nordisk Inc., Tandem Diabetes Care. 

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates each live and enduring ECHO for 1.0 AMA PRA Category 1 Credit. Please note that you must claim credit at the individual ECHO level. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each ECHO will have a live and on-demand component; please note that participation in the live event is limited to 25 persons per event and that those who participate in the live ECHO may receive credit from the live event but are not eligible to receive credit for the on-demand webinar. 

Please login using your Endocrine Society credentials. If you do not have an account with us, you will be prompted to create one.

To gain access to each live ECHO and the recordings for previous ECHOs, you must complete the program questionnaire by clicking 'Start.' Additionally, you will be asked to complete a short pre-survey for each ECHO you are interested in after registering on that activity's page.

Those registered for the live component will have access to a case submission portal after completing the pre-survey for each ECHO. This can be used to submit cases and questions specific to each topic.

Each live ECHO is open to 25 participants, and will take place the 3rd Thursday of every month September 2020-March 2021.

If you have any questions, please contact